Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones

Nature

Volumn 511, Issue 7507, 2014, Pages 94-98

  Maianti, Juan Pablo ^a   McFedries, Amanda ^a   Foda, Zachariah H ^b   Kleiner, Ralph E ^a   Du, Xiu Quan ^c   Leissring, Malcolm A ^d   Tang, Wei Jen ^e   Charron, Maureen J ^c   Seeliger, Markus A ^b   Saghatelian, Alan ^a   Liu, David R ^a  

^a HARVARD UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; ANTIDIABETIC AGENT; ENZYME INHIBITOR; GLUCAGON; GLUCOSE; INSULIN DEGRADING ENZYME INHIBITOR; MACROCYCLIC COMPOUND; UNCLASSIFIED DRUG;

DIABETES; ENZYME ACTIVITY; GLUCOSE; HOMEOSTASIS; HORMONE; INHIBITOR; PHYSIOLOGICAL RESPONSE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CATALYST; CRYSTAL STRUCTURE; FEASIBILITY STUDY; GLUCOSE TOLERANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH EMPTYING;

MUS;

ANIMALS; BINDING SITES; BLOOD GLUCOSE; CATALYTIC DOMAIN; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GASTRIC EMPTYING; GENETIC PREDISPOSITION TO DISEASE; GLUCAGON; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; INSULYSIN; ISLET AMYLOID POLYPEPTIDE; MACROCYCLIC COMPOUNDS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; OBESITY; SIGNAL TRANSDUCTION; THINNESS;

EID: 84903751880     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13297     Document Type: Article

References (28)

1. Duckworth, W. C., Bennett, R. G. & Hamel, F. G. Insulin degradation: progress and potential. Endocr. Rev. 19, 608-624 (1998).
2. Mirsky, I. A. & Broh-Kahn, R. H. The inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts. Arch. Biochem. 20, 1-9 (1949).
3. Sladek, R. et al.A genome-wide association study identifies novel risk loci for type2 diabetes. Nature 445, 881-885 (2007).
4. Zeggini, E. et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336-1341 (2007).
5. Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 4162-4167 (2003).
6. Abdul-Hay, S. O. et al. Deletion of insulin-degrading enzyme elicits antipodal, agedependent effects on glucose and insulin tolerance. PLoS ONE 6, e20818 (2011).
7. Gartner, Z. J. et al. DNA-templated organic synthesis and selection of a library of macrocycles. Science 305, 1601-1605 (2004).
8. Tse, B. N., Snyder, T. M., Shen, Y. & Liu, D. R. Translation of DNA into a library of 13,000 synthetic small-molecule macrocycles suitable for in vitro selection. J. Am. Chem. Soc. 130, 15611-15626 (2008).
9. Kim, Y. G., Lone, A. M., Nolte, W. M. & Saghatelian, A. Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides. Proc. Natl Acad. Sci. USA 109, 8523-8527 (2012).
10. Leissring, M. A. et al. Designed inhibitors of insulin-degrading enzymeregulate the catabolism and activity of insulin. PLoS ONE 5, e10504 (2010).
11. Malito, E. et al. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. Biochemistry 47, 12822-12834 (2008).
12. Malito, E., Hulse, R. E. & Tang, W. J. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 65, 2574-2585 (2008).
13. Shen, Y., Joachimiak, A., Rosner, M. R. & Tang, W. J. Structures of human insulindegrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870-874 (2006).
14. Manolopoulou, M., Guo, Q.,Malito, E., Schilling, A. B.&Tang, W. J. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J. Biol. Chem. 284, 14177-14188 (2009).
15. Stella, V. J. & He, Q. Cyclodextrins. Toxicol. Pathol. 36, 30-42 (2008).
16. Andrikopoulos, S., Blair, A. R., Deluca, N., Fam, B. C. & Proietto, J. Evaluating the glucose tolerance test in mice. Am. J. Physiol. Endocrinol. Metab. 295, E1323-E1332 (2008).
17. Ahrén, B., Winzell, M. S. & Pacini, G. The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. J. Endocrinol. 197, 181-187 (2008).
18. Winzell, M. S. & Ahren, B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 (Suppl 3), S215-S219 (2004).
19. Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153-165 (2006).
20. Riddle, M. C. & Drucker, D. J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29, 435-449 (2006).
21. Mooradian, A. D. & Thurman, J. E. Drug therapy of postprandial hyperglycaemia. Drugs 57, 19-29 (1999).
22. Duckworth, W. C. & Kitabchi, A. E. Insulin and glucagon degradation by the same enzyme. Diabetes 23, 536-543 (1974).
23. Bennett, R. G., Duckworth, W. C. & Hamel, F. G. Degradation of amylin by insulindegrading enzyme. J. Biol. Chem. 275, 36621-36625 (2000).
24. Young, A. Effects on plasma glucose and lactate. Adv. Pharmacol. 52, 193-208 (2005).
25. Gedulin, B. R., Jodka, C. M., Herrmann, K.&Young, A. A. Role of endogenous amylin in glucagonsecretion and gastricemptying in ratsdemonstrated with the selective antagonist, AC187. Regul. Pept. 137, 121-127 (2006).
26. Gelling, R. W. et al. Lower blood glucose, hyperglucagonemia, andpancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc.Natl Acad. Sci.USA100, 1438-1443 (2003).
27. Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4-12 (2012).
28. Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nature Rev. Endocrinol. 9, 425-433 (2013).